GlassScriptPhysician profile
Heather Jaeger
NPI 1144719733
$1,292.87
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $370 · 2023: $18.53 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.43 | 2021-2022 | |
| Abbott Laboratories | $155.36 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3, Freestyle Libre 2 |
| Radius Health, INC. | $138.88 | 2021 | |
| Amgen INC. | $126.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $98.26 | 2021-2022 | |
| Lilly USA, LLC | $92.98 | 2021-2022 | |
| Abbvie INC. | $85.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $75.39 | 2021-2022 | |
| Organon LLC | $38.14 | 2021-2022 | |
| Pfizer INC. | $31.91 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $22.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2021 | |
| Glaxosmithkline, LLC. | $15.75 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.89 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Jaeger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.